Rapid bupropion-induced hepatotoxicity: a case report and review of the literature

Anandabaskaran, Sulakchanan; Ho, Vincent

doi:10.1186/s13256-018-1563-9

Cited by 5 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 45 In our study, bupropion had 38,648 reported adverse events, but no signals were detected in DILI. Based on the literature, we found less than 10 reported cases 46 of hepatotoxicity considered to be induced by bupropion. Hepatotoxicity may be a rare adverse effect; however, physicians should be aware that bupropion has caused a fatal case 47 of hepatotoxicity with autoimmune features.…”

Section: Discussionmentioning

confidence: 98%

Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis

Jiang,

Wei,

Zhu

et al. 2024

Therapeutic Advances in Drug Safety

View full text Add to dashboard Cite

Background: Antidepressants are widely used to manage depression and other psychiatric diseases. A previous study revealed that hepatotoxicity was the main adverse event related to antidepressants. Therefore, drug-induced liver injury (DILI) caused by antidepressants deserves more attention. Objectives: To investigate DILI adverse events reported due to antidepressant use in the United States Food and Drug Administration Adverse Events Reporting System (FAERS) database. Research design: A disproportionality analysis of spontaneously reported adverse events was conducted to assess the association between antidepressant drugs and DILI. Methods: FAERS data from 1 January 2004 to 31 December 2021 were compiled and analyzed using the reporting odds ratio (ROR) and information component (IC). Results: As per the FAERS database, of the 324,588 cases that were administered antidepressants, 10,355 were identified as cases with DILI. Among the identified 42 antidepressants, nefazodone ( n = 47, ROR = 7.79, IC = 2.91), fluvoxamine ( n = 29, ROR = 4.69, IC = 2.20), and clomipramine ( n = 24, ROR = 3.97, IC = 1.96) had the highest ROR for cholestatic injury; mianserin ( n = 3, ROR = 21.46, IC = 3.99), nefazodone ( n = 264, ROR = 18.67, IC = 3.84), and maprotiline ( n = 15, ROR = 5.65, IC = 2.39) for hepatocellular injury; and nefazodone ( n = 187, ROR = 12.71, IC = 0.48), clomipramine ( n = 35, ROR = 2.07, IC = 0.26), and mirtazapine ( n = 483, ROR = 1.96, IC = 0.94) for severe drug-related hepatic disorders. Only nefazodone elicited hepatic failure signals ( n = 48, ROR = 18.64, IC = 4.16). There are limited reports on the adverse reactions of relatively new antidepressant drugs, such as milnacipran, viloxazine, esketamine, and tianeptine, and those not approved by the Food and Drugs Administration, such as reboxetine and agomelatine. Conclusion: A significant association was observed between DILI and nefazodone. Duloxetine and clomipramine were associated with three DILI categories, except hepatic failure. The disproportionality analysis cannot conclude on a definite causal link between antidepressants and DILI. Additional research is required to assess new-generation antidepressants for their propensity to cause DILI.

show abstract

Section: Discussionmentioning

confidence: 98%

Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis

Jiang,

Wei,

Zhu

et al. 2024

Therapeutic Advances in Drug Safety

View full text Add to dashboard Cite

show abstract

“…В нескольких случаях имели место иммуноаллергические проявления, выраженные в минимальной степени. Имеются сообщения о единичных случаях развития острой печеночной недостаточности с летальным исходом и хронического гепатита на фоне лечения обоими препаратами [16,19].…”

unclassified

Drug-induced liver injury with cholestasis in the neurologist and psychiatric practice

Остроумова

Ших

Shikh

et al. 2022

RJTAO

View full text Add to dashboard Cite

Among drug-induced liver injuries (DILI), the cholestatic type is second in frequency (from 20 to 40%), the most common is the hepatocellular variant (up to 78%). For this reason, practitioners of various specialties, including neurologists and psychiatrists, do not monitor cholestasis parameters, and drug-induced liver injury with cholestasis (DILIС) remains unrecognized. The urgency of this problem is great, because the frequency of deaths in DILIС is only slightly lower than t in the hepatocellular type; in addition, it DILIС is much more likely to become persistent increasing the risk of chronic liver injury.Among the drugs used in neurology and psychiatry, the “leaders” in terms of the number of DILIС are antidepressants, both tricyclic (amitriptyline, imipramine) and selective serotonin reuptake inhibitors (SSRIs: paroxetine, sertraline, fluoxetine, citalopram, escitalopram), antidepressants), antipsychotics (chlorpromazine, fluphenazine), anticonvulsants (mainly carbamazepine).If the patient has a history of DILI caused by any of the forementioned medications, the agent should be switched to another drug from the same group with a minimal risk of DILI. If there is a history of DILI associated with antidepressants, it is recommended to choose SSRIs. It is necessary to monitor not only the activity of transaminases and bilirubin, but also the cholestasis parameters (alkaline phosphatase, γ-glutamyl transpeptidase) during treatment.

show abstract

Bupropion

2018

Reactions Weekly

View full text Add to dashboard Cite

Rapid bupropion-induced hepatotoxicity: a case report and review of the literature

Abstract: We conclude that hepatotoxicity is a rare adverse effect of bupropion use, but physicians should be aware of the possibility of this potentially serious clinical picture of drug-induced hepatotoxicity with varied clinical presentation and prognosis.

Cited by 5 publications

References 12 publications

Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis

Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis

Drug-induced liver injury with cholestasis in the neurologist and psychiatric practice

Bupropion

Contact Info

Product

Resources

About